Exhibit 107
Calculation of Filing Fee Table
Form 424(b)(5)
(Form Type)
Rocket Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Security Type | Security Class Title | Fee Calculation or Carry Forward Rule | Amount Registered | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee |
| Newly Registered Securities |
| Fees to Be Paid | Equity | Common Stock, $0.01 par value | Rule 457(r) | 15,180,000 (1) | $12.50 | $189,750,000 (2) | 0.00015310 | $29,050.73 (3) |
| | Total Offering Amounts | | $189,750,000 | | $29,050.73 |
| | Total Fee Offsets | | | | $ 0.00 |
| | Net Fee Due | | | | $29,050.73 |
(1) Represents 15,180,000 shares (inclusive of the 30-day option for the underwriters to purchase up to an additional 1,980,000 shares) of common stock, $0.01 par value per share, of Rocket Pharmaceuticals, Inc. that will be offered for sale pursuant to the final prospectus to which this exhibit is attached.
(2) The proposed maximum aggregate offering price has been calculated based on 15,180,000 shares of common stock multiplied by $12.50 per share, the public offering price.
(3) Calculated in accordance with Rule 457(r) and 456(b) of the Securities Act of 1933, as amended. This “Calculation of Filing Fee Tables” shall be deemed to update the “Calculation of Filing Fee Tables” in the registrant’s registration statement on Form S-3ASR filed with the U.S. Securities and Exchange Commission on August 16, 2024 (File No. 333-281606).
The prospectus supplement to which this exhibit is attached is a final prospectus supplement for the related offering.
424B5 0001281895 EX-FILING FEES true S-3 333-281606 0001281895 2024-12-11 2024-12-11 0001281895 1 2024-12-11 2024-12-11 xbrli:shares iso4217:USD xbrli:pure
